Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 207

1.

Inpatient burden of esophageal varices in the United States: analysis of trends in demographics, cost of care, and outcomes.

Solanki S, Haq KF, Chakinala RC, Khan Z, Aronow WS, Ali Khan M, Siddiqui MT, Haq KS, Frager S, Alimirah M, Nabors C, Samson DJ, Lebovics E, Wolf DC.

Ann Transl Med. 2019 Sep;7(18):480. doi: 10.21037/atm.2019.08.34.

2.

Heart Transplantation for Hepatitis C Virus Non-Viremic Recipients From Hepatitis C Virus Viremic Donors.

Frager SZ, Dhand A, Gass A, Levine A, Spielvogel D, Nog R, Wolf DC, Bodin RI.

Cardiol Rev. 2019 Jul/Aug;27(4):179-181. doi: 10.1097/CRD.0000000000000255.

PMID:
31180937
3.

Soil bacterial community dynamics following surfactant addition and bioaugmentation in pyrene-contaminated soils.

Wolf DC, Cryder Z, Gan J.

Chemosphere. 2019 Sep;231:93-102. doi: 10.1016/j.chemosphere.2019.05.145. Epub 2019 May 18.

PMID:
31128356
4.

Chemical carcinogenicity revisited 2: Current knowledge of carcinogenesis shows that categorization as a carcinogen or non-carcinogen is not scientifically credible.

Doe JE, Boobis AR, Dellarco V, Fenner-Crisp PA, Moretto A, Pastoor TP, Schoeny RS, Seed JG, Wolf DC.

Regul Toxicol Pharmacol. 2019 Apr;103:124-129. doi: 10.1016/j.yrtph.2019.01.024. Epub 2019 Jan 18. Review.

5.

Chemical carcinogenicity revisited 1: A unified theory of carcinogenicity based on contemporary knowledge.

Wolf DC, Cohen SM, Boobis AR, Dellarco VL, Fenner-Crisp PA, Moretto A, Pastoor TP, Schoeny RS, Seed JG, Doe JE.

Regul Toxicol Pharmacol. 2019 Apr;103:86-92. doi: 10.1016/j.yrtph.2019.01.021. Epub 2019 Jan 8. Review.

6.

Chemical carcinogenicity revisited 3: Risk assessment of carcinogenic potential based on the current state of knowledge of carcinogenesis in humans.

Cohen SM, Boobis AR, Dellarco VL, Doe JE, Fenner-Crisp PA, Moretto A, Pastoor TP, Schoeny RS, Seed JG, Wolf DC.

Regul Toxicol Pharmacol. 2019 Apr;103:100-105. doi: 10.1016/j.yrtph.2019.01.017. Epub 2019 Jan 8. Review.

7.

A simple problem formulation framework to create the right solution to the right problem.

Sauve-Ciencewicki A, Davis KP, McDonald J, Ramanarayanan T, Raybould A, Wolf DC, Valenti T.

Regul Toxicol Pharmacol. 2019 Feb;101:187-193. doi: 10.1016/j.yrtph.2018.11.015. Epub 2018 Dec 1.

PMID:
30513358
8.

Influence of rhamnolipid biosurfactant and Brij-35 synthetic surfactant on 14C-Pyrene mineralization in soil.

Wolf DC, Gan J.

Environ Pollut. 2018 Dec;243(Pt B):1846-1853. doi: 10.1016/j.envpol.2018.10.031. Epub 2018 Oct 5.

PMID:
30408872
9.

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis.

Feagan BG, Schreiber S, Wolf DC, Axler JL, Kaviya A, James A, Curtis RI, Geransar P, Stallmach A, Ehehalt R, Bokemeyer B, Khalid JM, O'Byrne S.

Inflamm Bowel Dis. 2019 May 4;25(6):1028-1035. doi: 10.1093/ibd/izy323.

10.

Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.

Rutgeerts P, Gasink C, Chan D, Lang Y, Pollack P, Colombel JF, Wolf DC, Jacobstein D, Johanns J, Szapary P, Adedokun OJ, Feagan BG, Sandborn WJ.

Gastroenterology. 2018 Oct;155(4):1045-1058. doi: 10.1053/j.gastro.2018.06.035. Epub 2018 Aug 29.

PMID:
29909019
11.

Adherence rates and health care costs in Crohn's disease patients receiving certolizumab pegol with and without home health nurse assistance: results from a retrospective analysis of patient claims and home health nurse data.

Wolf DC, Jaganathan S, Burudpakdee C, Seetasith A, Low R, Lee E, Gucky J, Yassine M, Schwartz DA.

Patient Prefer Adherence. 2018 May 21;12:869-878. doi: 10.2147/PPA.S148777. eCollection 2018.

12.

Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials.

Panaccione R, Sandborn WJ, D'Haens G, Wolf DC, Berg S, Maa JF, Petersson J, Robinson AM.

J Crohns Colitis. 2018 Jul 30;12(8):930-938. doi: 10.1093/ecco-jcc/jjy050.

13.

Diagnosis, Treatment, and Management of Orthotopic Liver Transplant Candidates With Portopulmonary Hypertension.

Koulava A, Sannani A, Levine A, Gupta CA, Khanal S, Frishman W, Bodin R, Wolf DC, Aronow WS, Lanier GM.

Cardiol Rev. 2018 Jul/Aug;26(4):169-176. doi: 10.1097/CRD.0000000000000195. Review.

PMID:
29608499
14.

Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model.

Sanon NT, Gagné J, Wolf DC, Aboulamer S, Bosoi CM, Simard A, Messiet E, Desgent S, Carmant L.

Epilepsy Behav. 2018 Feb;79:117-125. doi: 10.1016/j.yebeh.2017.11.019. Epub 2017 Dec 26.

PMID:
29287214
15.

Challenges in Using Real-world Clinical Practice Records for Validation of Clinical Trial Data in Inflammatory Bowel Disease: Lessons Learned.

Afzali A, Ciorba MA, Schwartz DA, Sharaf M, Fourment C, Ritter T, Wolf DC, Shafran I, Randall CW, Kane SV.

Inflamm Bowel Dis. 2017 Dec 19;24(1):2-4. doi: 10.1093/ibd/izx015.

PMID:
29272481
16.

Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease.

Sandborn WJ, Wolf DC, Kosutic G, Parker G, Schreiber S, Lee SD, Abraham B, Afzali A, Arsenescu RI, Gutierrez A, Spearman M, Coarse J, Feagan BG.

Inflamm Bowel Dis. 2017 Jul;23(7):1047-1056. doi: 10.1097/MIB.0000000000001100.

PMID:
28410341
17.

Response to Loomis et al Comment on Boobis et al.

Boobis AR, Cohen SM, Dellarco VL, Doe JE, Fenner-Crisp PA, Moretto A, Pastoor TP, Schoeny RS, Seed JG, Wolf DC.

Regul Toxicol Pharmacol. 2017 Aug;88:358-359. doi: 10.1016/j.yrtph.2017.02.011. Epub 2017 Feb 16. No abstract available.

PMID:
28212846
19.

Classification schemes for carcinogenicity based on hazard-identification have become outmoded and serve neither science nor society.

Boobis AR, Cohen SM, Dellarco VL, Doe JE, Fenner-Crisp PA, Moretto A, Pastoor TP, Schoeny RS, Seed JG, Wolf DC.

Regul Toxicol Pharmacol. 2016 Dec;82:158-166. doi: 10.1016/j.yrtph.2016.10.014. Epub 2016 Oct 22.

20.

Reply.

Wolf DC.

Inflamm Bowel Dis. 2016 Sep;22(9):E32. doi: 10.1097/MIB.0000000000000878. No abstract available.

PMID:
27542140
21.

A predictive data-driven framework for endocrine prioritization: a triazole fungicide case study.

Paul Friedman K, Papineni S, Marty MS, Yi KD, Goetz AK, Rasoulpour RJ, Kwiatkowski P, Wolf DC, Blacker AM, Peffer RC.

Crit Rev Toxicol. 2016 Oct;46(9):785-833. doi: 10.1080/10408444.2016.1193722. Epub 2016 Jun 27. Review.

22.

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.

Sandborn WJ, Feagan BG, Wolf DC, D'Haens G, Vermeire S, Hanauer SB, Ghosh S, Smith H, Cravets M, Frohna PA, Aranda R, Gujrathi S, Olson A; TOUCHSTONE Study Group.

N Engl J Med. 2016 May 5;374(18):1754-62. doi: 10.1056/NEJMoa1513248.

23.

Biosimilars in Crohn's Disease and Ulcerative Colitis.

Wolf DC.

Inflamm Bowel Dis. 2016 Apr;22(4):994-7. doi: 10.1097/MIB.0000000000000673. Review. No abstract available.

PMID:
26933749
24.

The frequency of spontaneous seizures in rats correlates with alterations in sensorimotor gating, spatial working memory, and parvalbumin expression throughout limbic regions.

Wolf DC, Bueno-Júnior LS, Lopes-Aguiar C, Do Val Da Silva RA, Kandratavicius L, Leite JP.

Neuroscience. 2016 Jan 15;312:86-98. doi: 10.1016/j.neuroscience.2015.11.008. Epub 2015 Nov 12.

PMID:
26582750
25.

Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol.

Clowse ME, Wolf DC, Förger F, Cush JJ, Golembesky A, Shaughnessy L, De Cuyper D, Mahadevan U.

J Rheumatol. 2015 Dec;42(12):2270-8. doi: 10.3899/jrheum.140189. Epub 2015 Nov 1.

26.

Illustrative case using the RISK21 roadmap and matrix: prioritization for evaluation of chemicals found in drinking water.

Wolf DC, Bachman A, Barrett G, Bellin C, Goodman JI, Jensen E, Moretto A, McMullin T, Pastoor TP, Schoeny R, Slezak B, Wend K, Embry MR.

Crit Rev Toxicol. 2016;46(1):43-53. doi: 10.3109/10408444.2015.1082973. Epub 2015 Oct 9. Review.

27.

The management of eosinophilic gastroenteritis.

Gupta N, Aggarwal A, Gupta R, Sule S, Wolf DC.

Scand J Gastroenterol. 2015;50(11):1309-14. doi: 10.3109/00365521.2015.1049655. Epub 2015 Jun 1. Review.

PMID:
26027839
28.

Effects of nitric oxide-related compounds in the acute ketamine animal model of schizophrenia.

Kandratavicius L, Balista PA, Wolf DC, Abrao J, Evora PR, Rodrigues AJ, Chaves C, Maia-de-Oliveira JP, Leite JP, Dursun SM, Baker GB, Guimaraes FS, Hallak JE.

BMC Neurosci. 2015 Mar 7;16:9. doi: 10.1186/s12868-015-0149-3.

29.

Nematodes as bioindicators of ecosystem recovery during phytoremediation of crude oil contaminated soil.

Savin MC, Wolf DC, Davis KJ, Gbur EE, Thoma GJ.

Int J Phytoremediation. 2015;17(1-6):182-90. doi: 10.1080/15226514.2013.876964.

PMID:
25361231
30.

Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.

Colombel JF, Sandborn WJ, Ghosh S, Wolf DC, Panaccione R, Feagan B, Reinisch W, Robinson AM, Lazar A, Kron M, Huang B, Skup M, Thakkar RB.

Am J Gastroenterol. 2014 Nov;109(11):1771-80. doi: 10.1038/ajg.2014.242. Epub 2014 Aug 26.

31.

Dose and temporal effects on gene expression profiles of urothelial cells from rats exposed to diuron.

Ihlaseh-Catalano SM, Bailey KA, Cardoso AP, Ren H, Fry RC, de Camargo JL, Wolf DC.

Toxicology. 2014 Nov 5;325:21-30. doi: 10.1016/j.tox.2014.08.005. Epub 2014 Aug 23.

PMID:
25152437
32.

Evaluation of thoracic limb loads, elbow movement, and morphology in dogs before and after arthroscopic management of unilateral medial coronoid process disease.

Galindo-Zamora V, Dziallas P, Wolf DC, Kramer S, Abdelhadi J, Lucas K, Nolte I, Wefstaedt P.

Vet Surg. 2014 Oct;43(7):819-28. doi: 10.1111/j.1532-950X.2014.12250.x. Epub 2014 Jul 30.

PMID:
25073482
33.

Risk assessment in the 21st century: roadmap and matrix.

Embry MR, Bachman AN, Bell DR, Boobis AR, Cohen SM, Dellarco M, Dewhurst IC, Doerrer NG, Hines RN, Moretto A, Pastoor TP, Phillips RD, Rowlands JC, Tanir JY, Wolf DC, Doe JE.

Crit Rev Toxicol. 2014 Aug;44 Suppl 3:6-16. doi: 10.3109/10408444.2014.931924. Review.

PMID:
25070414
34.

A 21st century roadmap for human health risk assessment.

Pastoor TP, Bachman AN, Bell DR, Cohen SM, Dellarco M, Dewhurst IC, Doe JE, Doerrer NG, Embry MR, Hines RN, Moretto A, Phillips RD, Rowlands JC, Tanir JY, Wolf DC, Boobis AR.

Crit Rev Toxicol. 2014 Aug;44 Suppl 3:1-5. doi: 10.3109/10408444.2014.931923. Review.

PMID:
25070413
35.

Impact of Cardiovascular Risk Factors on Long-Term Mortality After Liver Transplantation.

Lai HM, Pawar R, Wolf DC, Aronow WS.

Am J Ther. 2016 Mar-Apr;23(2):e357-62. doi: 10.1097/MJT.0b013e31829c4c5f.

PMID:
24897624
36.

Timing of hepatic artery reperfusion and biliary strictures in liver transplantation.

Gunasekaran G, Sharma J, Mosna LC, Bodin R, Wolf DC.

J Transplant. 2013;2013:757389. doi: 10.1155/2013/757389. Epub 2013 Dec 3.

37.

Mode of action and human relevance analysis for nuclear receptor-mediated liver toxicity: A case study with phenobarbital as a model constitutive androstane receptor (CAR) activator.

Elcombe CR, Peffer RC, Wolf DC, Bailey J, Bars R, Bell D, Cattley RC, Ferguson SS, Geter D, Goetz A, Goodman JI, Hester S, Jacobs A, Omiecinski CJ, Schoeny R, Xie W, Lake BG.

Crit Rev Toxicol. 2014 Jan;44(1):64-82. doi: 10.3109/10408444.2013.835786. Epub 2013 Nov 4. Review.

38.

Capsule endoscopy is superior to small-bowel follow-through and equivalent to ileocolonoscopy in suspected Crohn's disease.

Leighton JA, Gralnek IM, Cohen SA, Toth E, Cave DR, Wolf DC, Mullin GE, Ketover SR, Legnani PE, Seidman EG, Crowell MD, Bergwerk AJ, Peled R, Eliakim R.

Clin Gastroenterol Hepatol. 2014 Apr;12(4):609-15. doi: 10.1016/j.cgh.2013.09.028. Epub 2013 Sep 27.

PMID:
24075891
39.
40.

Quality indicators for inflammatory bowel disease: development of process and outcome measures.

Melmed GY, Siegel CA, Spiegel BM, Allen JI, Cima R, Colombel JF, Dassopoulos T, Denson LA, Dudley-Brown S, Garb A, Hanauer SB, Kappelman MD, Lewis JD, Lynch I, Moynihan A, Rubin DT, Sartor RB, Schwartz RM, Wolf DC, Ullman TA.

Inflamm Bowel Dis. 2013 Mar;19(3):662-8. doi: 10.1097/mib.0b013e31828278a2. Erratum in: Inflamm Bowel Dis. 2013 Aug;19(9):2040.

PMID:
23388547
41.

Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease.

Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, Ullman T, Glover S, Valentine JF, Rubin DT, Miller J, Abreu MT.

Clin Gastroenterol Hepatol. 2013 Mar;11(3):286-92; quiz e24. doi: 10.1016/j.cgh.2012.11.011. Epub 2012 Nov 28.

42.

Community Perspectives: Combining Serology, Genetics, and Inflammation Markers for the Diagnosis of IBD and Differentiation Between CD and UC.

Wolf DC, Abraham BP, Afzali A, Allegretti PD, Arai R.

Gastroenterol Hepatol (N Y). 2012 Jun;8(6 Suppl 2):1-16.

43.

A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease.

Sands BE, Katz S, Wolf DC, Feagan BG, Wang T, Gustofson LM, Wong C, Vandervoort MK, Hanauer S.

Gut. 2013 Sep;62(9):1288-94. doi: 10.1136/gutjnl-2011-300995. Epub 2012 Jul 3.

PMID:
22760005
44.

Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.

Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Reinisch W; EXTEND Investigators, Kumar A, Lazar A, Camez A, Lomax KG, Pollack PF, D'Haens G.

Gastroenterology. 2012 May;142(5):1102-1111.e2. doi: 10.1053/j.gastro.2012.01.035. Epub 2012 Feb 8.

PMID:
22326435
45.

Can we direct organ allocation based on predicted outcome? Hepatocellular carcinoma outside of UCSF criteria or retransplant?

Rochon C, Sheiner P, Mahadevappa B, Gunasekaran G, Sharma J, Wolf DC, Facciuto M.

Langenbecks Arch Surg. 2012 Jun;397(5):711-5. doi: 10.1007/s00423-012-0910-3. Epub 2012 Jan 28.

PMID:
22282322
46.

Identification and characterization of adverse effects in 21st century toxicology.

Keller DA, Juberg DR, Catlin N, Farland WH, Hess FG, Wolf DC, Doerrer NG.

Toxicol Sci. 2012 Apr;126(2):291-7. doi: 10.1093/toxsci/kfr350. Epub 2012 Jan 19.

47.

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.

Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, Kron M, Tighe MB, Lazar A, Thakkar RB.

Gastroenterology. 2012 Feb;142(2):257-65.e1-3. doi: 10.1053/j.gastro.2011.10.032. Epub 2011 Nov 4.

PMID:
22062358
48.

Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: evaluation of radiological and pathological response.

Facciuto ME, Singh MK, Rochon C, Sharma J, Gimenez C, Katta U, Moorthy CR, Bentley-Hibbert S, Rodriguez-Davalos M, Wolf DC.

J Surg Oncol. 2012 Jun 1;105(7):692-8. doi: 10.1002/jso.22104. Epub 2011 Sep 29.

PMID:
21960321
49.

Liver transplantation for hepatocellular carcinoma: defining the impact of using extended criteria liver allografts.

Facciuto ME, Singh MK, Katta U, Samaniego S, Sharma J, Rodriguez-Davalos M, Sheiner P, Kim-Schluger L, Wolf DC.

Transplantation. 2011 Aug 27;92(4):446-52. doi: 10.1097/TP.0b013e3182252733.

PMID:
21694662
50.

Transcriptional profile of diuron-induced toxicity on the urinary bladder of male Wistar rats to inform mode of action.

Ihlaseh SM, Bailey KA, Hester SD, Jones C, Ren H, Cardoso AP, Oliveira ML, Wolf DC, de Camargo JL.

Toxicol Sci. 2011 Aug;122(2):330-8. doi: 10.1093/toxsci/kfr108. Epub 2011 May 7.

PMID:
21551480

Supplemental Content

Support Center